ATOPALM

ATOPALM is a South Korean skincare brand built around a patented skin-barrier technology and aimed at sensitive, dry and atopic skin. It is the flagship line of Neopharm Co., Ltd., a Korean dermocosmetics company founded in 2000, and was launched the same year [5][6]. The brand name joins "ATO", for atopic skin, with "PALM", evoking the soothing touch of a hand — a reference to its origin as a response to a child's atopic dermatitis.

The brand remains active. Its products are sold in South Korea, the United States, China and, more recently, the Nordic market, and the parent company sits alongside three sister brands in Neopharm's sensitive-skin portfolio.

ATOPALM grew out of a personal problem. According to a business interview with Neopharm, the founder, a research scientist, watched his newborn son struggle with dry, cracked and painful skin and found commercial products either ineffective or unsuitable. He set out to formulate a gentle, hypoallergenic alternative himself, drawing on a background that included work at Aekyung Industrial's central research laboratory.

Sources name the founder in two forms. Korean-language and patent records identify him as Dr. Park Byeong Deog [5], while the brand's UK distributor refers to him by the Westernized name Dr. Raymond Park [7]; the two refer to the same person, with the Korean form used on patent filings and formal recognitions. Neopharm Co., Ltd. was established in Korea in 2000 and ATOPALM became its first line for sensitive and atopic skin [5].

ATOPALM is owned by Neopharm Co., Ltd., the Korean company that holds the brand's core technology patent [6]. Neopharm runs a family of sensitive-skin brands positioned for different users: ATOPALM for baby and sensitive-skin care, Real Barrier and Derma:B for adult skincare, and ZEROID for clinical and dermatological use. In a published interview, the company's leadership presented these four brands as a single portfolio unified by its barrier-repair technology.

The brand positions itself as dermatologist-developed skincare for compromised skin, summed up by the company motto "Good Skin, Good Life", which frames skin health as part of overall wellbeing. ATOPALM describes its products as gentle and hypoallergenic, and says it emphasizes quality, safety and results rather than cosmetic trends. Its stated audience is broad within a narrow concern: people with sensitive skin, atopic dermatitis, eczema or rosacea, from infants and expectant mothers to adults. The brand is described as "100% made in Korea" [4].

ATOPALM's identity centres on its Multi-Lamellar Emulsion (MLE) technology, which the company says mimics the layered lipid structure that binds together the outermost skin cells, helping the formula absorb quickly and reinforce a weakened barrier. The technology is protected by a patent filed by Neopharm, "Multi-lamellar emulsion (MLE) for stabilizing dermatologically useful ingredients", with a priority date of February 2001 [6]. The patent describes maintaining a specific oil-to-emulsifier ratio intended to help restore a compromised barrier and to stabilize active ingredients, including reducing side effects from pharmaceutical agents such as steroids.

The brand's signature products are the MLE Cream and MLE Lotion, supported by items such as an intensive moisturizing cream and a maternity stretch-mark cream. Alongside the MLE system, formulas draw on ingredients including ceramides, panthenol, hyaluronic acid, peptides and vitamin E. The company states its products are dermatologist tested and developed for sensitive skin, eczema and rosacea. Neopharm has also cited research links to Professor Peter Elias at the University of California, San Francisco, as well as Korean university hospitals.

According to the brand's UK distributor, ATOPALM was rated the number-one brand in South Korea for sensitive skin from 2007 [7]. In 2017, the founder, Dr. Park Byeong Deog, was included in Marquis Who's Who for his work in dermatological research [5].

ATOPALM is an active brand. The most recent activity recorded in the source material is an October 2023 article published by its UK distributor, and the brand continues to be sold through its US storefront (theatopalm.com), its UK distributor (atopalm.co.uk) and Nordic retailers. The publicly listed US contact address, in Staten Island, New York, belongs to the brand's US distribution operation rather than the Korean parent; the specific city of Neopharm's Korean headquarters is not stated in the available sources.